---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-065672"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T06:51:07.576464+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Acadia Q1 revenue +19% to $244.3M; net income $19M; ACP-101 results accelerated to Q4 2025

## Summary
- Total Q1 revenue $244.3M, up 19% YoY; NUPLAZID sales $159.7M (+23%), DAYBUE $84.6M (+11%)
- Net income $19.0M ($0.11/sh) vs $16.6M ($0.10/sh) in Q1 2024; cash $681.6M
- DAYBUE record 954 unique patients shipped; 30% field force expansion completed; first EU patient served
- COMPASS PWS Phase 3 topline results now expected early Q4 2025 (accelerated); if positive, NDA submission Q1 2026
- 2025 guidance reiterated: total rev $1.03-1.095B; R&D expense raised to $330-350M due to study acceleration

## SEC filing metadata
- accession: 0000950170-25-065672
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017025065672/0000950170-25-065672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017025065672/acad-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-065672
- JSON: https://secwatch.observer/filing/0000950170-25-065672.json
- Plain text: https://secwatch.observer/filing/0000950170-25-065672.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.